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Hair exerts a range of functions including thermoregulation, physical protection, 
sensory activity. Mature and actively growing hair follicles become anchored in 
the subcutis, and regenerate by spontaneous repetitive cycles of growth 
(anagen), apoptosis-driven regression (catagen), and quiescence (telogen). We 
focused our study on investigating the effect of new therapeutic molecules 
capable of counteracting  the regression phase. We have tested our working 
hypothesis on HFDPC cells, grown in culture in Follicle Dermal Papilla Growth 
Medium, and apoptosis was induced by 24 hours incubation with 1 µM 
staurosporin. This treatment resulted in a marked activation of Caspase-3 
accompanied by cytoskeletal degradation, nuclear blebbing, and cellular 
fragmentation. The addition of spermidin or rutine in the micromolar range 
concentration reduced staurosporin-induced caspase activity by over 50%, 
when the two agents were added simultaneously equal levels of caspase-3 
inhibition was achieved with concentration 10 fold lower. Zeaxantine alone was 
ineffective, however when added to the combined spermidin and rutine 
treatment, the staurosporin-induced caspase activity was almost totally 
counteracted and the enzymatic activity was significantly reduced. These 
combined treatment was also effective in preventing staurosporin-mediated 
cellular damage. The extent of cell loss was greatly reduced and there was a 
total preservation and normal distribution of actin-tubulin cytoskeleton with 
normal cellular shape. Interestingly, our combined treatment also counteracted 
caspase-3 over-expression induced by staurosporin. In conclusion, this 
sperimental molecules can counteract HFDPC cells apoptosis and may 
represent an effective preventing treatment for the catagen phase of the hair 
bulb life cycle. 
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1.1 Hair Follicle 
 
The hair follicle (HF) is located in the dermis and subcutaneous tissue. It is a 
skin appendage with complex structure and functions, formed by an indentation 
of epithelium [Weinberg et al.]. It is considered one of the most important model 
for study on development and regeneration of tissues and organs, as it has a 
comparatively small size and has the characteristics of self-renewal and cycling 
growth [Gambarella et al.; Brouard et al.; Trueb].  
Dermal papilla cells (DPCs) are a group of dermal cells located in the bulbar 
zone of HF. They are a group of specific fibroblasts that represent a main 
component in the mesenchyma of HF, and play a leading role in regulating the 
development and cycling regeneration of HFs [Roh et al.; Botchkarev et al.; 
Rendl et al.]. During the initial stage of HF morphogenesis, DPCs can self-
aggregate in the dermis and induce an epidermal placode (an area of 
thickening in the embryonic epithelial layer where an organ or structure later 
develops) to form follicular structures [Stenn et al.; Millar]. DPCs are 
mesenchymal cells, and can thus differentiate into a variety of cell types, and 
they have been shown to induce neogenesis of HFs in hairless skin [Osada et 
al.; McElwee et al.]. It should be noted that the ability of DPCs to induce HF 
formation depends on their aggregative growth; defined as a multiradial growth 
phenomenon occurring before fusion of DPCs, and is a defining characteristic 
of DPCs that are able to induce HF formation. DPCs that grow in an 
aggregative manner are polygonal, with multiple protuberances, and are 
arranged in a radial pattern.  
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A hair follicle (HF) cycles through anagen (growth), catagen (involution) and 
telogen (resting) phases, and then re-enters the anagen phase (Figure 1). Each 
hair passes through the phases independent of the neighbouring hairs 
[Matsusaki et al.] 
Approximately 85% of all hairs are in the growing phase at any one time. The 
Anagen phase, or growth phase, can vary from two to six years. Hair grows 
approximately 10cm per year and any individual hair is unlikely to grow more 
than one meter long. At the end of the Anagen phase the hairs enters into a 
Catagen phase which lasts about one or two weeks, during the Catagen phase 
the hair follicle shrinks to about 1/6 of the normal length. The lower part is 
destroyed and the dermal papilla breaks away to rest below. The resting phase 
follows the catagen phase and normally lasts about 5-6 weeks. During this time 
the hair does not grow but stays attached to the follicle while the dermal papilla 
stays in a resting phase below. Approximately 10-15 percent of all hairs are in 
this phase at an one time. At the end of the Telogen phase the hair follicle re-
enters the Anagen phase. The dermal papilla and the base of the follicle join 
together again and a new hair begins to form. If the old hair has not already 
been shed the new hair pushes the old one out and the growth cycle starts all 
over again. 
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                                                                             [from: Marlon R. Schneider et al 2009 Current Biology 19, R132–R142] 
Figure 1. Key stages of the hair cycle. 
 
The hair cycle is divided into three phases: Anagen (growth phase), catagen (regression 
phase) and telogen (resting phase). Postnatal hair morphogenesis leads to elongation of the 
follicle and production of the hair fibre, which emerges from the skin. Once the hair follicle has 
matured, it enters the regression phase, during which the lower, cycling portion of the hair 
follicle is degraded. This process brings the dermal papilla into close proximity of the bulge, 
where the hair stem cells (HSCs) reside. The molecular interaction between the HSCs and the 
dermal papilla is essential to form a new hair follicle. The proximity between bulge and dermal 
papilla is maintained throughout telogen, the resting phase. Only when a critical concentration 
of hair growth activating signals is reached, anagen phase is entered and a new hair is re-
grown. The first postnatal hair cycle is initiated and passed by all hair follicles at the same time 
point, while subsequent cycles are no longer synchronized. Stages 1–8 of embryonic hair 
development are depicted (upper left), demonstrating the continuous transition between hair 
follicle development and the first postnatal hair cycle. APM: arrector pili muscle; DC, dermal 
condensate (green); DP: dermal papilla (green); HS: hair shaft  (brown); IRS: inner root sheath 
(blue); MC: melanocytes; ORS: outer root sheath; SC: sebocytes (yellow); SG: sebaceous 
gland. 
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At the base of this cycle is the ability of HF stem cells to briefly exit their 
quiescent status to generate transient amplifying progeny [Kligman]. It seems 
that, within a single hair follicle, periodic activation of beta-catenin in bulge stem 
cells is responsible for their cyclic activity. During HF growth and hair 
production, the activity of factors promoting the proliferation, differentiation and 
survival predominates. HF regression , or catagen, is characterized by 
activation of pathways that induce apoptosis in HF cells (Figure 2). Data 
Obtained from murine and human HF suggest that apoptosis could be 
controlled both by extrinsic and intrinsic pathways [Schneider et al.]. 
 
 
                         [from: Botchkareva et al. (2006) J Inv. Dermatol. 126: 258-64] 
Fig. 2 Anti- and pro-apoptotic molecules expressed in distinct  hair follicule 
compartments 
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Distinct cell populations in the HF posses differential susceptibility to apoptosis. 
The most susceptible to apoptosis are the majority of the follicular epithelial 
cells and melanocytes, whereas dermal papilla fibroblasts, some of the 
keratinocytes and melanocytes selected for survival, are resistant to apoptosis. 
HF development and cycling are controlled by similar signalling networks within 
and between the follicular epithelium and mesenchyme, using the molecules 
that belong to the bone morphogenwtic protein (BMP)/TGF-beta, EGF, FGF, 
IGF, neurotrophin, TNF, and Wnt families [Langbein et al.]. Recent studies 
suggest regulation of HF homeostasis by dermal papillar cells  through the 
autocrine and paracrine production of specific factors, from which an important 
role is attributed to a Dkk family proteins [Kwack et al.]. The exposure of dermal 
papillar cells to dihydrotestosterone determines the up-regulation of DKK1, that 
is then secreted thereby triggering the apoptosis of outer root sheath 
keratinocytes. Differently the expression of IGF-1 by follicular dermal papillar 
cells is promoted by finasteride treatment of androgenic alopecia [Wakisaka et 
al.; Weger et al.]. 
 
 
1.2 Androgenetic alopecia 
 
Androgenetic alopecia is a common form of hair loss in both men and women. 
In men, this condition is also known as male-pattern baldness. Hair is lost in a 
well-defined pattern, beginning above both temples. Over time, the hairline 
recedes to form a characteristic "M" shape. Hair also thins at the crown (near 
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the top of the head), often progressing to partial or complete baldness [Muller; 
Hamilton]. 
The pattern of hair loss in women differs from male-pattern baldness. In 
women, the hair becomes thinner all over the head, and the hairline does not 
recede. Androgenetic alopecia in women rarely leads to total baldness. 
Androgenetic alopecia in men has been associated with several other medical 
conditions including coronary heart disease and enlargement of the prostate 
[Lesko et al.]. Additionally, prostate cancer, disorders of insulin resistance 
(such as diabetes and obesity), and high blood pressure (hypertension) have 
been related to androgenetic alopecia [Ellis et al.; Oh et al.; Hawk et al.; 
Ahouansou et al.]. In women, androgenetic alopecia is associated with an 
increased risk of polycystic ovary syndrome (PCOS). PCOS is characterized by 
a hormonal imbalance that can lead to irregular menstruation, acne, excess 
body hair (hirsutism), and weight gain [Rathnayake et al.]. 
Although androgenetic alopecia is a frequent cause of hair loss in both men 
and women, it is more common in men. This form of hair loss affects an 
estimated 35 million men in the United States. Androgenetic alopecia can start 
as early as a person's teens and risk increases with age; more than 50 percent 
of men over age 50 have some degree of hair loss. In women, hair loss is most 
likely after menopause [Ludwig]. 
A variety of genetic and environmental factors likely play a role in causing 
androgenetic alopecia. Although researchers are studying risk factors that may 
contribute to this condition, most of these factors remain unknown. 
Researchers have determined that this form of hair loss is related to  
androgens hormones, particularly dihydrotestosterone. Androgens are 
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important for normal male sexual development before birth and during puberty 
[Kaufman] . 
Androgens also have other important functions in both males and females, 
such as regulating hair growth and sex drive. 
Hair growth begins under the skin in the follicles. Each strand of hair normally 
grows for 2 to 6 years, goes into a resting phase for several months, and then 
falls out. The cycle starts over when the follicle begins growing a new hair. 
Increased levels of androgens in hair follicles can lead to a shorter cycle of hair 
growth and the growth of shorter and thinner strands of hair. Additionally, there 
is a delay in the growth of new hair to replace strands that are shed [Olsen]. 
Although researchers suspect that several genes play a role in androgenetic 
alopecia, variations in only one gene, AR, have been identified in people with 
this condition. The AR gene provides instructions for making  androgen 
receptor. Androgen receptor is the intracellular protein that mediates biological 
actions of physiological androgens (testosterone and 5 alpha-
dihydrotestosterone). Androgen receptor belongs to a large family of ligand-
dependent proteins whose function is to modulate expression of genes and 
gene networks in a cell- and tissue-specific manner [Janne].  
Androgen receptors allow the body to respond appropriately to 
dihydrotestosterone and other androgens. Studies suggest that variations in the 
AR gene lead to increased activity of androgen receptors in hair follicles. It 
remains unclear, however, how these genetic changes increase the risk of 
patterned hair loss in men and women with androgenetic alopecia. 
Researchers continue to investigate the connection between androgenetic 
alopecia and other medical conditions, such as coronary heart disease and 
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prostate cancer in men and polycystic ovary syndrome in women. They believe 
that some of these disorders may be associated with elevated androgen levels, 
which may help explain why they tend to occur with androgen-related hair loss. 
Other hormonal, environmental, and genetic factors that have not been 
identified also may be involved [Hawk] . 
The inheritance pattern of androgenetic alopecia is unclear because many 
genetic and environmental factors are likely to be involved. This condition tends 
to cluster in families, however, and having a close relative with patterned hair 
loss appears to be a risk factor for developing the condition [Muller;Hamilton]. 
         
 
1.3 Apoptosis 
 
Apoptosis is a common mechanism among multicellular organisms to eliminate 
cells that are no longer needed or have become damaged. It is a 
morphologically and biochemically distinct form of cell death that can be 
triggered by a wide range of internal and external signals. 
 It occurs in response to environmental or developmental cues, cellular 
stresses, and specific cell death signals. This self-inflicte death, named for a 
characteristic rounding and “falling off” of cells, involves a number of 
evolutionarily conserved biochemical pathways that have been intensively 
studied for over two decades [Taylor et al.]. Apoptotic cell death is generally 
characterized by an inward collapse of organelles, a “blebbing” of the plasma 
membrane into vesicular apoptotic bodies, and the destruction of genetic 
material [Ferri et al.]. The molecular events regulating apoptosis are dependent 
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on cell type as well as the context of death induction. Nonetheless, key 
molecular milestones are common to many of modes of cell death. Apoptosis is 
essential during the development of multicellular organisms [Kuida et al.]. It 
also eradicates damaged or virally infected cells throughout the life of an 
organism in the absence of an inflammatory response [Savill et al]. It does this 
by engaging a series of coordinated changes in cell structure/behaviour that 
culminate in the presentation of surface markers that flag the dying cell for 
engulfment by professional or non-professional phagocytes [Savill et al.]. For 
this to occur, dying cells must retain the capacity to control the 
organisation/positioning of membranes and proteins long enough to bring about 
their recognition by phagocytes. Most observers consider the execution phase 
of apoptosis - the time during which gross apoptotic morphological/behaviour 
changes are observed and before the cell begins the process of secondary 
necrosis - to last for around 1-2 hours [Mills et al.; Moss et al.]. Hence, a dying 
cell has a limited time window during which it must coordinate both the changes 
in morphology that are required for its isolation and the exposure of novel 
and/or altered surface moieties that are needed for efficient recognition and 
engulfment. 
 
 
1.3.1 Apoptotic signalling: basic principles 
Apoptosis can be induced by an array of toxic insults, physiological and non-
physiological, which all converge on the activation of a family of proteases 
called caspases [Earnshaw et al.; Fan et al.]. These enzymes are present in 
the cytosol of all viable cells as zymogens with low intrinsic activity, providing 
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cells with the capability to rapidly trigger apopotic protease action without the 
need for new protein synthesis. Apoptotic caspases fall into two general 
classes: the initiator caspases that are required for initial apoptotic signalling 
and the executioner caspases whose roles are to cleave a variety of important 
structural and regulatory proteins at conserved aspartic acid residues to alter 
their functions irreversibly [Earnshaw et al.; Taylor et al.]. Members of the Bcl-2 
family of pro- and anti-apoptotic signalling molecules integrate these signals, 
and their interactions dictate whether or not a cell enters the 
apoptotic execution phase. Importantly, many of these are known to associate 
with organelles of the endomembrane system or with cytoskeletal components 
[Betin et al.]. Of particular importance are the interactions between Bcl-2 family 
members and the mitochondria which harbour an array of apoptotic signalling 
molecules whose release via Bcl-2 family engagement triggers a robust 
apoptotic response; although relationships between Bcl-2 family members and 
the endoplasmic reticulum (ER) are also significant particularly with respect to 
calcium signalling or in cells subject to oxidative stress [Ferri et al.]. Induction of 
mitochondrial outer membrane permeabilisation (MOMP) via Bcl-2 family 
members causes release of cytochrome c, which, in turn, activates the initiator 
caspase-9 by inducing assembly of the “apoptosome” - a complex consisting of 
multiple copies of caspase-9, cytochrome c, dATP and the adaptor APAF-1. 
Caspase-9, in turn, activates effector caspases that cleave target proteins to 
initiate the apoptotic execution phase proper. Mitochondria are therefore central 
to a cell’s apoptotic response. The other major mechanism for activating 
caspases in response to death stimuli is via cell surface engagement of death 
receptors such as those of the TNF family (e.g. Fas receptor/CD95). Death 
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receptors can activate caspases directly, or via mitochondrial amplification. As 
transmembrane proteins that exert their influence at the plasma membrane, 
their trafficking through the secretory and endocytic systems is a key feature of 
death receptor signalling. It has become apparent that both the secretory and 
endocytic systems are disrupted as an early consequence of caspase 
activation, but it is unclear how this impacts upon death receptor distribution, 
trafficking and signalling “Executioner” caspases such as caspase-3 carry out 
the final, committed steps of the apoptotic program after activation of upstream, 
apical “initiator” caspases, such as caspase-8, which activate apoptosis 
through two generalized pathways (Figure 3). Capsase- 3 (also known as 
CPP32, Yama or apopain) is the most important apoptosis effector. In 
quiescent conditions caspase- 3 is inactive (pro-enzyme), following pro-
apoptotic stimuli it become processed and activated by caspases-8 and-9.   
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 Figure 3. Essential pathways to caspase activation and cell death  
Apoptosis is initiated by internal cellular stress or extracellularly through the binding of ligands 
to cell surface death receptors. Type I pathways directly activate executioner caspases through 
initiator caspases to result in death. In Type II pathways, death signals are routed through the 
Bcl-2 proteins such as Bid and the mitochondria to control the release of cytochrome c. 
Cytosolic cytochrome c binds Apaf-1 to activate the apoptosome and caspase-9 to result in 
executioner caspase-3 activation and cell death. 
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1.3.2 Apoptotic cell remodelling 
The dramatic changes in cell behaviour observed during the apoptotic 
execution phase are orchestrated by caspases. In response to targeted protein 
cleavage, apoptotic cells begin a process of remodelling which includes cell 
retraction, plasma membrane blebbing and often fragmentation of the cell into 
membrane-bound apoptotic bodies. In epithelia the execution phase also 
invokes the actions of neighbouring cells that respond to early changes in the 
dying cell (possibly allied to cytoskeletal deregulationand changes in lateral 
tensile resistance) to initiate its extrusion [Rosenblatt et al.]. Extrusion then 
follows a regulated sequence of events involving the redistribution of actin and 
microtubule cytoskeletons within neighbouring cells to squeeze the dying cell 
(usually apically) via p115 RhoGEF-mediated actin contractility [Slattum et al.]. 
Fragmentation is also largely actin/myosin II driven [Mills et al; Moss et al.], and 
probably aids cell engulfment [Moss et al.] while also providing carriers for the 
dispersal of potent autoimmune factors [Savill et al.]. Live-cell imaging of cells 
treated with a variety of apoptosis inducing factors suggests that surface 
blebbing is one of the earliest morphological features of the execution phase 
[Lane et al]. Surface blebbing is a regulated process requiring caspase 
cleavage and activation of the Rho effector, ROCK1 and remodelling of the 
actin cytoskeleton (Coleman et al.; Sebbagh et al.]. Its exact roles are not 
understood, but these may include apoptotic cell recognition, cytoplasmic 
mixing and energy depletion [Sebbagh et al.]. In adherent cells, blebbing and 
retraction begin simultaneously, although addition of myosin II inhibitors (such 
as blebbistatin) prevents blebbing but does not block cell retraction, suggesting 
that these processes are not mutually dependent [Lane et al.]. Close inspection 
                                                                                                              
    
 21
of adherent cells in isolation suggests that blebbing is biphasic (Fig. 1): the 
early blebbing phase begins concomitant with cell retraction, is characterised 
by numerous, small, dynamic blebs and lasts for around 40 minutes; the 
second phase is initiated after a brief pause, and is associated with fewer, large 
blebs that decorate the cell surface asymmetrically [Lane et al.]. Importantly, 
non-adherent cell-lines demonstrate only a single phase of blebbing, and these 
blebs are equivalent to the late blebs in adherent cells onaccount of their 
morphology and timing in relation to exposure of the plasma membrane inner 
leaflet lipid, phosphatidyl serine (PS) [Lane et al.]. These observations suggest 
that early blebbing is initiated during cell retraction and is restricted to adherent 
cell types, an important consideration when comparing the apoptotic phenotype 
across different cell lineages. Equally, our observations that the active 
redistribution of membranes and organelle fragments into surface blebs 
correlates with late blebbing [Lane et al.], suggest that it is this stage of 
remodelling that is important for the final stages of apoptotic cell partitioning 
and eventual disposal. 
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1.4 EDA/EDAR Signaling Pathways in Hair Follicle Induction 
 
Hair follicle development requires reciprocal communication between surface 
epithelial cells and the underlying mesenchyme that is mediated by secreted 
signaling molecules.  Signaling from the placodes promotes clustering of 
underlying dermal fibroblasts, forming dermal condensates that are the 
precursors of hair follicle dermal papillae. Further signaling interactions 
between the hair placode and the nascent dermal papilla lead to placode down-
growth and hair follicle morphogenesis. Among known signaling mechanisms 
involved in hair follicle development, the Wnt/b-catenin and EDA/EDAR/NF-kB 
pathways appear to play the earliest roles [Hammerschmid et al.].  
Ectodysplasin receptor Edar and its ligand Eda A1, as well as their related 
receptor Xedar and ligand Eda A2, are members of the tumor necrosis factor 
superfamily that signal predominantly through the nuclear factor-kappaB and c-
jun N-terminal kinases pathways. Mutations in genes that encode proteins 
involved in Edar signaling pathway cause hypohidrotic ectodermal displasias in 
humans and mice and characterized by severe defects in development of 
ectodermal appendages including hairs, teeth, and exocrine glands [Cui et al.; 
Fessing et al.]. Expression of several Wnt ligands and Wnt reporter transgenes 
is specifically elevated in developing hair follicles, and forced activation of b-
catenin signalling promotes hair follicle fate in both embryonic and postnatal 
skin. Conversely, ectopic expression of the secreted Wnt inhibitor DKK1 in 
embryonic mouse epidermis prevents the initiation of hair follicle development 
and blocks patterned expression of all molecular placode markers, including 
Wnt ligands, suggesting the importance of an earlier acting, broadly expressed 
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Wnt signal [Andl et al.]. Binding of the A1 isoform of the Tumor Necrosis Factor 
a (TNFa) family member Ectodysplasin (EDA) to its receptor EDAR induces 
nuclear translocation of the transcription factor NF-kB, and NF-kB pathway 
activation in developing hair follicle placodes [Laurikkala et al.]. Eda-A1 (391 
aa) and Eda-A2 (389 aa) differ only by an insertion of two amino acids in the 
TNF domain due to the usage of alternative splice donor sites [Mikkola et al.]. 
Surprisingly, Eda-A1 and Eda-A2 were found to engage two different receptors: 
Edar is the specific receptor for Eda-A1 whereas X-linked Eda-A2 receptor 
(Xedar), another related but distinct TNFR binds Eda-A2, but not Eda-A1.Eda-
A1 and Eda-A2 isoforms are trimeric proteins produced as type II 
transmembrane proteins with a short N-terminal intracellular domain and a 
fairly large C-terminal extracellular domain containing a (G-X-Y)19 collagen-like 
repeat with one interruption followed by the TNF homology domain (see 
Figures 3 and 4) [Prodi et al.]. 
 
 
Figure 4. Schematic representation of ectodysplasin. 
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Figure 5. Summary of Edar and Xedar signal transduction pathways. Engagement of a 
cleaved form of Eda-A1 with Edar results in the formation of a complex containing the adapter 
proteins Edaradd and Traf family members leading eventually to the activation of NFK-B. Xedar 
is activated by Eda-A2 and can directly bind to Trafs. Traf6 is specifically required for the 
activation of NFK-B and JNK pathways by Xedar. 
 
The expression of ectodysplasin and Edar has been analyzed in detail during 
murine hair and tooth development (Figure 6) whereas there is only one report 
on the expression of Xedar. In general, Eda and Edar are restricted to the 
ectodermal cells, and where analyzed, Edaradd has been detected in the same 
cells as Edar . During early development, Eda and Edar are colocalized in the 
simple ectodermal sheet covering the embryo. Upon initiation of tooth (E11) 
and hair (E14) development Edar becomes restricted to the forming placodes 
whereas Eda shows complementary expression in the flanking ectoderm. For 
most part, the analysis of Eda expression has been done by in situ 
hybridization, which cannot distinguish between the two isoforms. No detailed 
expression data of Eda is available in adults. Northern blot analysis has 
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revealed expression of human Eda in heart, kidney, and pancreas, as well as 
weaker expression in brain, placenta, lung, liver, and skeletal muscle. This 
correlates fairly well with the analysis done in mice. Using a more sensitive RT-
PCR method, expression of Eda has been seen in practically all human tissues 
tested. [Midorikawa] In situ analysis shows that in adults, the expression is 
mainly epithelial. In addition to the affected organs, expression has been 
detected in kidney, sympathetic ganglia, hypothalamus, in the mammary gland 
epithelium, and in the duct epithelium of the prostate. The importance of the 
adult expression is currently not known. Expression of Eda has been studied 
only in few pathological situations. Its expression seems to be less abundant in 
both benign and malignant [Mikkola]. 
 
 
Figure 6. The development of a hair and a tooth.   
Both teeth and hairs form from surface epithelium and underlying mesenchyme and their 
development is regulated by interactions between the two tissues. The early stages are 
morphologically similar as the ectodermal placodes develop, form buds and induce the 
formation of the dermal and dental papillae. The hair shaft is formed by ectodermal matrix cells 
and during hair cycling new hair formation is initiated from stem cells in the bulge. In the tooth 
germ, epithelial folding is regulated by the enamel knot signaling center and it determines the 
shape of the tooth. 
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1.5 Wnt/DKK1 
 
During homeostasis, tissue renewal is tightly controlled by the Wnt pathway. 
However, during pathogenesis it seems that inhibitors of the Wnt pathway, 
such as DKK1, are upregulated and subsequently affect Wnt mediated repair 
mechanisms (figure 7) [Schmidt-Ullrich et al.]. Such diseases include multiple 
myeloma and rheumatoid arthritis, where in both cases it has been 
demonstrated that secretion of high levels of DKK1 is the cause of the bone 
lesions. Canonical WNT signals are transduced through Frizzled (FZD) family 
receptors and LRP5/LRP6 coreceptor to the β-catenin signaling cascade. In the 
absence of canonical WNT signaling, β-catenin complexed with APC and AXIN 
is phosphorylated by casein kinase Iα (CKIα) and glycogen synthase kinase 3β 
(GSK3β) in the NH2-terminal degradation box, which is polyubiquitinated by 
βTRCP1 or βTRCP2 complex for the following proteasome-mediated 
degradation . In the presence of canonical WNT signaling, Dishevelled (DVL) is 
phosphorylated by CKIα for high-affinity binding to FRAT. Because canonical 
WNT signal induces the assembly of FZD-DVL complex and LRP5/6-AXIN-
FRAT complex , β-catenin is released from phosphorylation by CKIα and 
GSK3β for stabilization and nuclear accumulation. [ Yang et al.] Nuclear β-
catenin is complexed with T-cell factor/lymphoid enhancer factor (TCF/LEF) 
family transcription factors and also with Legless family docking proteins (BCL9 
and BCL9L) associated with PYGO family coactivators (PYGO1 and PYGO2). 
The TCF/LEF-β-catenin-Legless-PYGO nuclear complex is the effector of the 
canonical WNT signaling pathway to activate the transcription of target genes 
such as FGF20, DKK1, WISP1, MYC, and CCND1. SFRP1, SFRP2, SFRP3, 
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SFRP4, SFRP5, WIF1, DKK1, DKK2, DKK3, and DKK4 are secreted-type WNT 
signaling inhibitors . SFRP family members and WIF1 are WNT antagonists 
that inhibit WNT binding to FZD family receptors [Zhao et al.]. DKK family 
members also are WNT antagonists, their interaction with LRP5/LRP6 
coreceptor and trigger its endocytosis to prevent formation of the WNT-FZD-
LRP5/LRP6 complex for the canonical WNT signaling. Recent studies suggest 
HF homeostasis is regulated by production autocrine and paracrine factors by 
dermal papillar cells, one of these factors is DKK-1 (rf). The incubation of 
dermal papillar cells with dihydrotestosterone determines the induction of 
DKK1. DKK1 mRNA is up-regulated in 3-6 hours after treatment with 50-100 
nM of dihydrotestosterone. ELISA assays showed that DKK-1 is secreted by 
dermal papillar cells triggering apoptosis of outer root sheath keratinocytes 
[Kwack et al]. 
 
 
Figure 7. Summary of Wnt/DKK1 relationship. The molecular action of Wnt is described 
following the numbers. The expression of DKK1 is regulated by the interaction of α-actin with 
DNA. DKK1 inhibits the Lpr5 interaction with Fz blocking the Wnt pathway  (step 9). 
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1.6 Akt and ERK kinases 
 
Protein kinases regulate diverse cellular functions through the orchestrated 
propagation and amplification of cellular stimuli into distinct biological 
responses through coordinated signal transduction cascades. With several 
hundred kinases encoded in the human genome, almost every signal 
transduction process is influenced by interconnected phosphorylation events. 
Deregulation of kinase activity has been implicated in various diseases, ranging 
from vascular disorders and inflammatory diseases to neurological disorders 
and cancer. Akt or Protein kinase B (PKB) is a member of the second 
messenger subfamily of protein kinases [Julien et al.]. The three isoforms of Akt 
identified have an amino-terminal pleckstrin homology domain, a central kinase 
domain, and a carboxy-terminal regulatory domain. Akt is the major 
downstream target of receptor tyrosine kinases that signal via the 
phosphoinositide (PI) 3-kinase. Receptor-activated PI 3-kinase synthesises the 
lipid second messenger PI-3,4,5-trisphosphate, leading to the recruitment of 
Akt to the membrane. Membrane attachment of Akt is mediated by its pleckstrin 
homology domain binding to PI-3,4,5-trisphosphate or PI-3,4-bisphosphate with 
high affinity. Activated Akt is implicated in glucose metabolism, transcriptional 
control, and in the regulation of apoptosis in many different cell types [Pellegrin 
et al.]. Stimulation of Akt activity protects cells from apoptosis by 
phosphorylation and inactivation of the pro-apoptotic protein BAD. Conserved 
signaling pathways that activate the mitogen-activated protein kinases 
(MAPKs) are involved in relaying extracellular stimulations to intracellular 
responses [Chen Q et al.]. The extracellular signal-regulated kinase (ERK) 
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MAPK pathway has been the subject of intense research leading to the 
development of pharmacologic inhibitors for the treatment of cancer [Gedaly et 
al.]. ERK is a downstream component of an evolutionarily conserved signalling 
module that is activated by the Raf serine/threonine kinases [Chen T et al.]. Raf 
activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, 
which then activate ERK1/2. Mitogen-activated protein kinase (MAPK) 
cascades are key signaling pathways involved in the regulation of normal cell 
proliferation, survival and differentiation. The ERK/MAPK pathway initially 
appeared as a linear pipeline that conveyed signals from cell surface receptors 
to ERK/MAPK, which distributed them to different effectors (figure 8) [Ashton-
Beaucage et al.].  
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Figure 8. The ERK/MAPK pathway.  On stimulation by mitogens such as epidermal growth 
factor (EGF), activated receptors recruit Ras guanine nucleotide-exchange factors, such as son 
of sevenless (SOS) through the adaptor protein growth-factor-receptor-bound-2 (Grb2), which 
generates Ras•GTP. Ras•GTP induces KSR dephosphorylation of S392 by stimulating the 
binding of the protein phosphatase-2A (PP2A) B subunit to its A and C subunits, which are 
constitutively associated with KSR. This results in the release of 14-3-3 from this KSR binding 
site and translocation of KSR to the cell membrane. KSR facilitates the phosphorylation of 
MAPK and ERK kinase (MEK) by Raf, and enhances the generation of activated extracellular 
signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK), which can 
phosphorylate both nuclear and non-nuclear substrates. [from Walter Kolch Nature Cell Biology 
2005] 
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1.7 Non synthetic molecules 
 
 
1.7.1 Rutin  
 
 
 
 
 
 Figure 9. Rutin: chemical and 3D structure    
                                                                                                                 
Rutin, also called rutoside, quercetin-3-rutinoside and sophorin, is a citrus 
flavonoid glycoside found in buckwheat, the leaves and petioles of Rheum 
species, and asparagus. Rutin is also found in the fruit of the Fava D'anta tree 
(from Brazil), fruits and fruit rinds especially citrus fruits (orange, grapefruit, 
lemon, lime) and berries such as mulberry and cranberries. Its name comes 
from the name of Ruta graveolens, a plant that also contains rutin. It is 
sometimes referred to Vitamin P, although not strictly a vitamin. Rutin is the 
glycoside between the flavonol quercetin and the disaccharide rutinose. In 
Fava d'anta, the synthetis is done via a rutin synthase activity.  Rutin can be 
created by bonding a disaccharide onto the hydroxyl group of Quercetin Rutin 
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(quercetin rutinoside), as well as quercitrin, is a glycoside of the flavonoid 
Quercetin. [Richetti et al.] As such, the chemical structures of both are very 
similar, with the difference existing in the Hydroxyl functional group. Both 
quercetin and rutin are used in many countries as medications for blood vessel 
protection and are ingredients of numerous multivitamin preparations and 
herbal remedies [Fonseca et al.]. It can combine with cations, supplying 
nutrients from the soil to the cells in plants. In humans, it attaches to the iron 
ion Fe2+, preventing it from binding to hydrogen peroxide, which would 
otherwise create a highly-reactive free-radical that may damage cells. It is also 
an antioxidant, and potent VEGF inhibitor (angiogenesis inhibitor), and, 
therefore, it has been suggested to play a role in inhibiting some cancers. Rutin 
inhibits platelet aggregation, as well as decreasing capillary permeability, 
making the blood thinner and improving circulation and it has anti-inflammatory 
activity [Almeida et al.]. Rutin inhibits aldose reductase activity. Aldose 
reductase is an enzyme normally present in the eye and elsewhere in the body. 
It helps change glucose into a sugar alcohol called sorbitol. Rutin also 
strengthens the capillaries, and, therefore, can reduce the symptoms of 
haemophilia. It also may help to prevent a common unpleasant-looking venous 
edema of the legs. Rutin, as ferulic acid, can reduce the cytotoxicity of oxidized 
LDL cholesterol and lower the risk of heart disease. There is also some 
evidence that Rutin can be used to treat hemorrhoids, varicosis, and 
microangiopathy. Hydroxyethylrutosides, synthetic hydroxyethyl acetylations of 
rutin, are used in the treatment of chronic venous insufficiency [Gong et al.]. 
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1.7.2 Spermidine 
 
 
Figure 10. Spermidine: chemical and 3D structure    
 
Spermidine is a polyamine involved in cellular metabolism that can be used to 
stimulate the enzyme T7 RNA polymerase, a type of RNA polymerase.  
Spermidine is a ubiquitous polycation that is synthesized from putrescine and 
serves as a precursor of spermine. Putrescine, spermidine and spermine all are 
polyamines that participate in multiple known and unknown biological 
processes. Exogenous supply of spermidine prolongs the life span of several 
model organisms including (yeast, nematodes, and flies) and significantly 
reduces agerelated oxidative protein damage in mice, indicating that this agent 
may act as a universal anti-aging drug.  Spermidine induces autophagy in 
cultured yeast and mammalian cells, as well as in nematodes and flies. Genetic 
inactivation of genes essential for autophagy abolishes the life span-prolonging 
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effect of spermidine in yeast, nematodes and flies. These findings complement 
expanding evidence that autophagy mediates cytoprotection against a variety 
of noxious agents and can confer longevity when induced at the whole-
organism level [Garcia-Faroldi et al.]. 
 
 
1.7.3 Zeaxanthin 
 
   Figure 11. Zeaxanthin: chemical and 3D structure    
 
Zeaxanthin is a bioflavonoid (or flavonoid), which is a type pigment found in 
almost all herbs, fruits, and vegetables. Bioflavonoids provide the body with 
anti-inflammatory and antioxidant protection, and are one of the main reasons 
fruits and vegetables are so healthy to eat. Zeaxanthin belongs to a group of 
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bioflavonoids known as carotenoids, a group that is further subdivided into two 
groups: carotenes and xanthophylls. Zeaxanthin is one of the xanthophylls, 
which are found most abundantly in dark, leafy green vegetables, and are 
crucial to the good health of the eyes [Ji HF]. The retina of the eye actually 
contains a lot of zeaxanthin; it helps protect the eye from ultra-violet (UV) 
damage, and prevents free-radical damage to the retina and the lens of the eye 
that is associated with diabetic retinopathy, macular degeneration, cataracts, 
and glaucoma [Bucheli et al.]. The best sources of zeaxanthin are dark-green 
leafy vegetables, such as greens, kale, and spinach. Zeaxanthin is also found 
in yellow fruits and vegetables, and egg yolks. Zeaxanthin is a fat-soluble 
nutrient, which means that it is best absorbed when taken along with foods that 
contain fat, or in combination with fatty-acid supplements such as fish oil and 
conjugated linoleic acid (CLA). People that have low-fat diets or diets lacking 
fruits and vegetables, or with physical conditions that prevent them from 
properly digesting fat, are at increased risk for carotenoid deficiency [Lecerf et 
al.]. 
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1.7.4 Epigallocatechin gallate 
        
Figure 12. Epigallocatechin gallate: chemical and 3D structure    
Epigallocatechin gallate (EGCG), also known as epigallocatechin 3-gallate, is 
the ester of epigallocatechin and gallic acid, and is a type of catechin. EGCG is 
the most abundant catechin in most notably tea, among other plants, and is 
also a potent antioxidant that may have therapeutic properties for many 
disorders including cancer [El-Mowafy et al.]. It is found in green tea, but not 
black tea, as EGCG is converted into thearubigins in black teas. In a high 
temperature environment, an epimerization change is likely to occur, because 
heating results in the conversion from EGCG to GCG. Thus it is considered 
inappropriate to infuse green tea or its extracts with overheated water. There 
has been research investigating the benefit of EGCG from green tea in the 
treatment of HIV infection, where EGCG has been shown to reduce plaques 
related to AIDS-related dementia in the laboratory, as well as block gp120 
[Monobe et al.]. However, these effects have yet to be confirmed in live human 
trials, and it does not imply that green tea will cure or block HIV infection, but it 
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may help regulate viral load as long as it is not involved in adverse drug 
reactions. The concentrations of EGCG used in the studies could not be 
reached by drinking green tea. More study into EGCG and HIV is currently 
underway. There is increasing evidence to show that EGCG, along with other 
flavonoids, can be beneficial in treating brain, prostate, cervical and bladder 
cancers. EGCG has been shown to bind and inhibit the anti-apoptotic protein 
Bcl-xl which has been implicated in both cancer cell and normal cell survival 
[Rocha et al.].  
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2. Aim 
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Androgenetic alopecia has been studied for years; it is very common but 
unfortunately its causes and therapies are still unknown. With our studying, 
only with non synthetic molecules, we suggest a way to prevent alopecia and 
delay its progress. 
Three active principles (Sperimidine, Rutin and Zeaxanthin) and their mixture 
were investigated on the regulation of the regression phase of hair cycle. The 
project was subdivided in two major:  
 
1) in vitro evaluation of anti-apoptotic activity in HFDP cells.  We evaluated it in 
different ways, but especially we measured the activity of caspese-3 in control 
cells, in apoptotic cells and apoptotic cells and the mixture. 
Its activity was investigated in many different ways; we did the special 
colorimetric assay,  where we analyzed the effect of every single molecules on 
this enzyme. That was the first step of our research, we could evaluate the 
activity of every single principle, of a couple of molecules and a mixture of three 
of them.  As it is shown in results the best inhibition of caspase-3 activity was 
made by the mixture of rutin, spermidine and zeaxanthin.  
We did also morphological evaluation of the activity of caspase-3 by analyzing 
HFDP cells morphology and how it changed in apoptosis and how it was 
preserved by using the mixture. 
With western blot analysis we could not only detect caspase 3 but also related 
envyme and AKT and Map kinases activity, strictly related with cell life. 
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2) ability to maintain molecular function in ex vivo human hair bulbs;  That was 
a very interesting assay that allowed us not only to taste the mixtures on cells 
but also ex vivo on human air bulbs.  
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3. Materials and 
Methods 
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3.1 HFDP cells culture 
 
Human follicle dermal papilla cells (HFDPC) are located in the dermal papilla at 
the base of hair follicles. This primary cells were obtained from Promocell at the 
passage 2  and were grown in Dermal Papilla Growth Medium in presence of 
fetal calf serum (FCS; 5% vol/vol) and growth factors (Human recombinant 
bFGF 100 ng/100ml medium; Bovine pituitary extract 0,4 ml/100 ml medium; 
Human recombinant insulin 500 microgr/100 ml medium. Cells were maintained 
at 37°C at 5% CO 2. 
 
 
3.2 Protein quantification 
 
To perform protein quantification we used the Quick Start™ Bradford protein 
assay (Biorad), which  is a fast, robust and simple one-step method for 
measuring protein concentrations samples in a variety of solutions. The 
Bradford method [Anal. Biochem. (1976) 72, 248-254] measures the 
absorbance shift of the red cationic form of Coomassie Blue G-250 to the blue 
stable anionic form when bound to arginine and hydrophobic amino acids in 
proteins. The assay is compatible with a wide range of reagents, such as 
organic solvents (acetone, acetonitrile, methanol), some detergents (CHAPS, 
desoxycholate, octylglucoside), most commonly used buffers (PBS, TRIS, 
Hepes), culture media (Eagles MEM), salt solutions (NaCl2, MgCl2, KCl), 
sugars (sucrose, glucose) and denaturating reagents (DTT, 2-mercaptoethanol, 
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urea). In this assay Serum Bovine Albumine (BSA) was used as standard. 
Each sample was quantitated in triple.   
 
 
3.3 RNA and Protein extraction 
 
Cell protein extracts were obtained by means of TRIzol™ reagent following 
manufacturer instructions (Invitrogen, Carlsbad, California). 
TRIZOL Reagent (U.S.Patent No.5,346,994) is a ready-to-use reagent for the 
isolation of total RNA from cells and tissues. The reagent, a mono-phasic 
solution of phenol and guanidine isothiocyanate, is an improvement to the 
single-step RNA isolation method developed by Chomczynski and Sacchi1. 
During sample homogenization or lysis, TRIZOL Reagent maintains the 
integrity of the RNA, while disrupting cells and dissolving cell components. 
Addition of chloroform followed by centrifugation, separates the solution into an 
aqueous phase and an organic phase. RNA remains exclusively in the aqueous 
phase. After transfer of the aqueous phase, the RNA is recovered by 
precipitation with isopropyl alcohol. After removal of the aqueous phase, the 
DNA and proteins in the sample can be recovered by sequential precipitation2. 
Precipitation with ethanol yields DNA from the interphase, and an additional 
precipitation with isopropyl alcohol yields proteins from the organic phase2. 
Copurification of the DNA may be useful for normalizing RNA yields from 
sample to sample. 
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3.3.1 RNA extraction: 
o Add 1 mL of TRIzol solution per 10 cm2 of culture dish area, and pass 
the cell lysate through a pipette several times to lyse cells and 
homogenize the sample.  
o Incubate the homogenate for 5 min at room temp. This 5 min room 
temperature incubation allows nucleoprotein complexes to completely 
dissociate. Homogenized samples can be stored at –70°C for at l east 
one month. 
o Centrifuge at 12,000 xg for 10 min at 4°C and tran sfer the supernatant to 
a fresh tube. 
o Add 200 µL chloroform per 1 mL of TRI Reagent solution. 
o Cap the tubes tightly and shake vigorously for 15 sec. 
o Incubate the mixture at room temperature for 10 min. 
o Centrifuge at 12,000 x g for 15 min at 4°C, then t ransfer the aqueous 
phase to a fresh tube. 
o Centrifuge at 12,000 x g for 15 min at 4°C. 
o RNA remains exclusively in the aqueous phase whereas DNA and 
protein are in the interphase and organic phase. The interphase and 
lower, red, organic phase can be stored 
o Add 500 µL of isopropanol per 1 mL of TRIzol solution vortex for 5–10 
sec, and incubate at room temp for 5–10 min. 
o Vortex at moderate speed for 5–10 sec. 
o Incubate the samples at room temp for 5–10 min. 
o Centrifuge at 12,000 x g for 8 min  and discard the supernatant. 
o Centrifuge at 12,000 x g for 8 min. 
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o Carefully remove the supernatant without disturbing the pellet. 
o Precipitated RNA forms a gel-like or white pellet on the side and bottom 
of the tube. 
o Add 1 mL of 75% ethanol per 1 mL of TRIzol solution. 
o Add 1 mL of 75% ethanol per 1 mL TRIzol solution used for sample 
homogenization to each sample to wash the RNA pellets. 
o Centrifuge at 7,500 x g for 5 min, remove the ethanol, and briefly air dry 
the RNA pellet. 
o Centrifuge at 7,500 x g for 5 min. 
o If the precipitated RNA floats or does not form a compact pellet, repeat 
the centrifugation at 12,000 x g for 5 min to consolidate the pellet at the 
bottom of the tube. 
o Remove the ethanol wash without disturbing the pellet. 
o Remove all residual ethanol by centrifuging again briefly and removing 
the ethanol that collects with a fine tip pipette. 
o Complete removal of ethanol is necessary for the RNA to perform well in 
downstream applications. 
o Air dry the RNA pellet for 3–5 min. 
o Do not completely dry the RNA pellet as this will greatly decrease its 
solubility. Do not dry RNA by vacuum centrifugation. 
o Dissolve RNA in the buffer of your choice and store at -70°. 
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3.3.2 Protein extraction: 
Protein are isolated from the phenol-ethanol supernatant obtained 
afterprecipitation of DNA with ethanol: 
o Add 1,5 mL of isopropanol per 1 mL of TRIzol 
o Store samples for 10 minutes at room temperature  
o Centrifugate at 12000 xg for 10 minutes 
o Remove the supernatant  
o Wash the protein pellet 3 times in a solution containing 0,3M 
guanidine hydrochloride in 95% ethanol. During each wash cycle, 
store the protein pelletin the wash solution for 20 minutes and 
centrifuga6te at 7.500 xg for 5 minutes. 
o After the final wash vortex the protein pellet in 2 mL of ethanol. 
o Store the protein pellet in ethanol for 20 minutes and centrifugate at 
7.500 xg for 5 minutes. 
o Vacuum dry the protein pellet for 5-10 minutes. 
o Dissolve it in 1% SDS by pipetting. 
Sediment any insoluble material by centrifugation at 10.000 xg for 10 minutes 
and transfer the supernatant to a fresh tube. The sample is ready for use in 
Western blotting or may be stored at -20° for futur e use. 
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3.4 SDS Page, Western blotting and protein detection 
 
3.4.1 Protein sample preparation for electrophoresis 
50-75 µg of protein samples (cell lysate or tissue homogenizated), previously 
TCA precipitated (paragraph 2.) or not, are combined with Novex Tris-Glycine 
SDS sample buffer 2X (Invitrogen) containing 5% 2-β mercaptoethanol (70mM) 
in a microcentrifuge tube. In the case of TCA precipitation, Tris buffer is 
sometimes added to adjust pH if TCA residues are still present in sample 
resuspension. Many proteins have significant hydrophobic properties and may 
be tightly associated with other molecules, such as lipids, through hydrophobic 
interaction. Heating the samples to at least 60°C s hakes up the molecules, 
allowing SDS to bind in the hydrophobic regions and complete the 
denaturation. Thus, the samples are boiled for 5-10 min to fully denature the 
proteins and left at room temperature until ready to load onto the gel. Molecular 
weight marker (5µL) (Bio-Rad) is aliquoted in a separate tube and boiled for 1 
min. 
 
3.4.2 SDS Page 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is 
probably the most common analytical technique used to separate and 
characterize proteins, using a discontinuous polyacrylamide gel as support 
medium and SDS to denature the proteins. SDS (also called lauryl sulfate) is 
an anionic detergent bound by a polypeptide chain in proportion to its relative 
molecular mass. The negative charges on SDS destroy most of the complex 
structure of proteins, and are strongly attracted toward an anode in an electric 
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field. Polyacrylamide gels restrain larger molecules from migrating as fast as 
smaller molecules. Because the charge-to-mass ratio is nearly the same 
among SDS-denatured polypeptides, the final separation of proteins is 
dependent almost entirely on the differences in relative molecular mass of 
polypeptides. In a gel of uniform density the relative migration distance of a 
protein (Rf) is negatively proportional to the log of its mass. If proteins of known 
mass are run simultaneously with the unknowns, the relationship between Rf 
and mass can be plotted, and the masses of unknown proteins estimated. 
Protein separation by SDS-PAGE can be used to estimate relative molecular 
mass, to determine the relative abundance of major proteins in a sample, and 
to determine the distribution of proteins among fractions. Acrylamide is the 
material of choice for preparing electrophoretic gels to separate proteins by 
size. Acrylamide mixed with bisacrylamide forms a cross-linked polymer 
network when the polymerizing agent, ammonium persulfate, is added. The 
ammonium persulfate produces free radicals faster in the presence of TEMED 
(N,N,N,N'-tetramethylenediamine). The size of the pores in a gel is inversely 
related to the amount of acrylamide used. Very large polypeptides cannot 
penetrate far into a gel and thus their corresponding bands may be too 
compressed for resolution. Polypeptides below a particular size are not 
restricted at all by the gel, and regardless of mass they all move at the same 
pace along with the tracking dye. Gel concentration (%T) should be selected to 
resolve precisely proteins of interest. A typical gel of 7% acrylamide 
composition separates polypeptides with molecular mass between 45 and 200 
kDa. There are two types of buffer systems used in PAGE electrophoresis: 
continuous and discontinuous systems. A continuous system has only a single 
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separating gel and uses the same buffer in the tanks and the gel. In a 
discontinuous system, a non-restrictive large pore gel, called stacking gel, is 
layered on top of a separating gel called resolving gel. Each gel is made with a 
different buffer, and the tank buffers are different from the gel buffers. The 
stacking gel has a lower concentration of acrylamide (larger pore size), lower 
pH and a different ionic content. This allows the proteins to be concentrated 
into a tight band before entering in the resolving gel. The resolving gel may 
consist of a constant acrylamide concentration or a gradient of acrylamide 
concentration (high percentage of acrylamide at the bottom of the gel and low 
percentage at the top). A gradient gel is prepared by mixing two different 
concentrations of acrylamide solution to form a gradient with decreasing 
concentrations of acrylamide. As the gradient forms, it is layered into a gel 
cassette. This latter gel is recommended for separation of a mixture of proteins 
with a greater molecular weight range. 
In our experimental conditions, continuous gel was running under reducing and 
denaturant conditions. Gel preparation procedures and running conditions used 
are described in the following protocol: 
o Assemble glass plate sandwich using two clean glass plates and two 75-
mm spacers. Assemble the casting frame and stand as described by 
manufacturer. 
o In a clean falcon, prepare the resolving gel solution, mixing the 
ingredients as described in Table 11, remembering that AP and TEMED 
must be added at the end. Be careful not to generate bubbles. 
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o Pour the resolving gel to a level about 1 cm from the top. Wait 1 min, 
then layer the top of the gel with saturated butyl alcohol (this will help the 
gel to solidify quickly in the absence of air). 
o Wait another 15-20 min for the gel to polymerize. Pour off the top layer 
of butyl alcohol and rinse with distilled water. Dry off as much of the 
water as possible, using absorbent paper. 
o In a clean falcon, prepare the stacking gel as described in Table 11, 
being careful not to generate bubbles. 
o Pour the resolving gel till the space is full, then put in the appropriate 
comb. (The difference in the pH of the two layers is what causes the 
stacking of the proteins. Thus, if the proteins are not stacking properly 
check the pH of the buffers). 
o Allow the top portion to solidify and then carefully remove the comb or 
store at 4°C in humidified condition, until use. 
o Place gel in opposite side of apparatus (Mini-PROTEAN 3-Cell, Bio-
Rad). 
o Slowly add 1x Running buffer. 
o Load samples and molecular weight marker. 
o Run the gel at 60V until the blue dye overpass stacking phase, and then 
run it at 110 V until the blue dye reaches the bottom or runs off. At this 
time, the run is stopped, cables removed. The gel is removed from the 
cassette and can be processed for western blotting. 
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Table 1. Resolving and Stacking gel solution recipes. 
Reagents Running gel (1x) Stacking gel (1x) 
Acrylamyde 
percentage 
7% 10% 12% 15% 3% 
dH2O (ml) 7.2 15.3 12.3 10.2 3.075l 
30%/0.8% 
Acrylamide/Bis (ml) 
7.5 7.5 7.5 7.5 1.25 
4x Lower Tris Buffer 
(ml) 
0.15 0.15 0.15 0.15 0.025 
10% SDS (ml) 15.0 6.9 9.9 12.0 0.67 
APS (ml) 0.15 0.15 0.15l 0.15 0.025 
TEMED (ml) 0.02 0.02l 0.02 0.02 0.005 
 
 
3.4.3 Western blotting and protein detection   
The term “blotting” refers to the transfer of biological samples from a gel to a 
membrane and their subsequent detection on the surface of the membrane. 
Western blotting was introduced by Towbin and collegues [1989] and is now a 
routine technique for protein analysis. The specificity of the antibody-antigen 
interaction enables a single protein to be identified in the midst of a complex 
protein mixture. Western blotting is commonly used to identify a specific protein 
in a complex mixture and to obtain qualitative and semiquantitative data about 
that. The first step in a western blotting procedure is to separate the 
macromolecules using gel electrophoresis. Following electrophoresis, the 
separated molecules are transferred onto a second matrix, generally a 
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nitrocellulose or polyvinylidene fluoride (PVDF) membrane. Next, the 
membrane is blocked to prevent any nonspecific binding of antibodies to the 
surface of the membrane. The transferred protein is complexed with an 
enzyme-labeled antibody as a probe. An appropriate substrate is then added to 
the enzyme and together they produce a detectable product such as a 
chromogenic or fluorogenic precipitate on the membrane for colorimetric or 
fluorimetric detection, respectively. The most sensitive detection methods use a 
chemiluminescent substrate that, when combined with the enzyme, produces 
light. This output can be captured using film, a CCD camera or a 
phosphorimager designed for chemiluminescent detection. Whatever substrate 
is used, the intensity of the signal correlates with the abundance of the antigen 
on the blotting membrane. In our experimental procedure, western blotting and 
protein detection protocols are the following: 
o Cut a piece of nitrocellulose membrane (Hybond-ECL, Amersham 
Biosciences). Wet the membrane in dH2O. Soak membrane in 1x 
Transfer buffer for 10 min. 
o Pre-wet the sponges, filter papers (slightly bigger than gel) in 1x 
Transfer buffer. Assemble sandwich (sponge-paper-gel-membrane-
paper-sponge) for the electroblotting apparatus (Mini Trans-Blot 
Electrophoretic Transfer Cell, Bio-Rad). 
o Transfer for 1 hr at 100 V with a cold pack and prechilled buffer. 
o After transfer is complete, turn off power supply and remove cathode 
plate of blotter. Remove transfer membrane and cut lower right corner of 
membrane to mark orientation of gel.  
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o Staining the membrane with Ponceau’s dye and the gel with Coomassie 
Blue dye to verify the correct transfer. 
o Remove Ponceau’s staining, washing the membrane with dH2O. 
o Block the nitrocellulose membrane in TBS with 0,05% Tween-20 (v/v) 
(T-TBS), containing 5% slim milk (w/v) for at least 60 min on a rocking 
platform. 
o Wash the nitrocellulose membrane 3 times in T-TBS for 10 min each on 
a rocking platform. 
o Incubate the nitrocellulose membrane on a rocking platform with primary 
antibody diluted in T-TBS, overnight at 4°C. 
o Wash the nitrocellulose membrane 3 times in T-TBS for 10 min each on 
a rocking platform. 
o Incubate with secondary antibody horseradish peroxidase-conjugate 
diluted in 5% milk T-TBS for 60-90 min on a rocking platform at room 
temperature. 
o Wash the nitrocellulose membrane 3 times in T-TBS for 10 min each on 
a rocking platform.  
o Wash the nitrocellulose membrane once in TBS to remove the excess of 
tween. 
o Detect proteins by means of an enhanced chemiluminescence detection 
system (ECLTM, Amersham). 
o After incubation of 5 min with ECL, blots are placed in a sheet protector 
and exposed to Kodak X-Omat Blue Film (Blue X-ray Film) (Perkin 
Elmer) for different times. Several exposures allow better densitometric 
analysis. 
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o Autoradiography films are automated processed with an Automated x-
ray film developer (Kodak M35A X-OMAT processor). 
Primary antibodies used in experimental procedures: 
o anti-β-actin, clone K3004 (diluition 1:1000 in T-TBS 0.05%) (Santa 
Cruz Biotechnology). 
o anti-Akt, (diluition 1:1000 in T-TBS 0.05%) (Cell Signaling). 
o anti-phospho Akt, (diluition 1:1000 in T-TBS 0.05%) (Cell Signaling). 
o anti-Erk, (diluition 1:1000 in T-TBS 0.05%) (Cell Signaling). 
o anti-phospho Erk, (diluition 1:1000 in T-TBS 0.05%) (Cell Signaling). 
o PARP, (diluition 1:200 in T-TBS 0.05%) (Santa Cruz Biotechnology). 
o Caspase-3, (diluition 1:200 in T-TBS 0.05%) (Santa Cruz 
Biotechnology). 
o EDA receptor, (diluition 1:1000 in T-TBS 0.05%) (R&D). 
Secondary antibodies used in experimental procedures: 
o anti rabbit IgG-HRP (diluition 1:10.000 in T-TBS 0.05%) (Chemicon 
International). 
o anti goat IgG-HRP (diluition 1:10.000 in T-TBS 0.05%) (Chemicon 
International). 
o Anti mouse IgG-HRP (diluition 1:5.000 in T-TBS 0.05%) (Chemicon 
International). 
  
Nitrocellulose membrane stripping 
After visualizing protein of interest, it is possible to strip off the first set of 
protein probes so that different proteins on the blot may be detected using a 
second set of specific probes. When possible, this technique saves the time 
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and resources that would be necessary to electrophorese another sample and 
transfer it to new sheet of membrane. Stripping generally involves soaking the 
blot in a buffer that is sufficiently harsh to dissociate the affinity interactions 
between antibodies and the target sample protein that was transferred to the 
membrane. The goal is to find a stripping condition that is efficient in removing 
the probes without also removing or damaging the target proteins on the blot. 
Because every antibody-antigen affinity interaction and target protein is unique, 
no one stripping condition is appropriate for all situations. Empirical testing and 
some optimization are necessary to determine appropriate stripping conditions 
for a particular western blot system. In most cases, conditions can be optimized 
to make at least one round of stripping and reprobing possible.In some cases, 
several rounds of stripping and reprobing are possible. 
In our experimental condition, the stripping protocol consists in: 
o Wash abundantly the nitrocellulose membrane with T-TBS on a rocking 
platform. 
o Incubate the membrane with Stripping Buffer at 50°C for 30 min. 
Adding 0.5 M NaCl to the stripping buffer slightly reduces the 
background from multiple probings. 
o Wash abundantly the nitrocellulose membrane with TBS on a rocking 
platform. 
o Return to membrane blocking and primary antibody incubation as 
previously described. 
Densitometric analysis 
Exposures of the same membrane for different times were acquired using 
GelDocTM image capture system (Bio-Rad), following Manufacturer’s 
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instructions. The autoradiograms were quantified using Quantity OneTM and 
Image J software. The data were then analyzed with suitable statistic 
methods.  
Polyacrylamide gel staining 
After western blotting procedure, gel staining allows to verify the correct 
loading of protein samples and the correct protein transfer to nitrocellulose 
membrane. A commonly used stain for detecting proteins in polyacrylamide 
gels is 0.1% Coomassie Blue dye in 50% methanol, 10% glacial acetic acid. 
Acidified methanol precipitates the proteins. Staining is usually performed 
overnight on a rocking platform. The dye penetrates the entire gel, and sticks 
permanently to the proteins. Excess dye is washed out by destaining 
procedure with acetic acid/methanol washes on a rocking platform. Destaining 
in two steps (first using 50% methanol, 10% acetic acid for 1-2 hours, and 
then using 7% methanol, 10% acetic methanol) provided a better efficiency. 
Finally, gels can be dried or photographed for later analysis.  
 
 
3.5 Caspase-3 activity 
 
The proteolytic activity of caspase-3 was evaluated by means of a colorimetric 
assay ApoTargetTMCaspase-3/CPP32 with DEVD-pNA as a substrate 
(BioSource International, Camarillo, CA). The colorimetric substrate (Ac-DEVD-
pNA) provided in the Assay System, Colorimetric, is labeled with the 
chromophore p-nitroaniline (pNA). pNA is released from the substrate upon 
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cleavage by DEVDase. Free pNA produces a yellow color that is monitored by 
a spectrophotometer at 405 nm. he amount of yellow color produced upon 
cleavage is proportional to the amount of DEVDase activity present in the 
sample. The assay was performed following the instructions of the provider. 
Briefly, for each sample was used the same amount of protein extract (200 g) 
and each sample was assyied in double. The measure of  absorbance at 405 
nm was performed by means of an automatic spettrofometer (MPT Reader 
DV990 BVG). 
 
 
3.6 Confocal microscopy 
 Confocal microscopy offers several advantages over conventional optical 
microscopy,including 
controllable depth of field, the 
elimination of image degrading 
out-of-focus information, and 
the ability to collect serial optical 
sections from thick specimens. 
The key to the confocal 
approach is the use of spatial 
filtering to eliminate out-of-focus 
light or flare in specimens that 
are thicker than the plane of focus. In recent years, there has been a 
tremendous explosion in the popularity of confocal microscopy, due in part to 
the relative ease with which extremely high-quality images can be obtained 
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Figure 14. Confocal microscopy image of 
Caspase-3 and Phalloidin immunostaining. 
Caspase3(RED) and Phalloidin (GREEN) 
staining was performed in HFDP cells, 
previously fixed on slide with paraphormaldeid 
procedure. In blue, nuclei staining with DAPI 
dye. Immunoflorescence image assessed 
from specimens prepared for conventional optical microscopy. In a 
conventional widefield microscope, the entire specimen is bathed in light from a 
mercury or xenon source, and the image can be viewed directly by eye or 
projected onto an image capture device or photographic film. In contrast, the 
method of image formation in a 
confocal microscope is 
fundamentally different. Illumination 
is achieved by scanning one or 
more focused beams of light, 
usually from a laser or arc-
discharge source, across the 
specimen. This point of illumination 
is brought to focus in the specimen 
by the objective lens, and laterally 
scanned using some form of scanning device under computer control. The 
sequences of points of light from the specimen are detected by a 
photomultiplier tube (PMT) through a pinhole (or in some cases, a slit), and the 
output from the PMT is built into an image and displayed by the computer 
(Figure 13). Although unstained specimens can be viewed using light reflected 
back from the specimen, they usually are labelled with one or more fluorescent 
probes.  
Specimen Preparation and Imaging  
The procedures for preparing and imaging specimens in the confocal 
microscope are largely derived from those that have been developed over 
many years for use with the conventional wide field microscope. In the 
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biomedical sciences, a major application of confocal microscopy involves 
imaging either fixed (Figure 14) or living cells and tissues   have usually been 
labeled with one or more fluorescent probes. A large number of fluorescent 
probes are available that, when incorporated in relatively simple protocols, 
specifically stain certain cellular organelles and structures. Among the plethora 
of available probes are dyes that label nuclei, the Golgi apparatus, the 
endoplasmic reticulum, and mitochondria, and also dyes such as fluorescently 
labelled phalloidins that target polymerized actin in cells. Regardless of the 
specimen preparation protocol employed, a primary benefit of the way in which 
confocal microscopy is carried out is the flexibility in image display and analysis 
that results from the simultaneous collection of multiple images, in digital form, 
into a computer . 
Critical aspects of Confocal microscopy 
Quantitative three-dimensional imaging in fluorescence microscopy is often 
complicated by artifacts due to specimen preparation (e.g. autofluorescence 
problems, retractile structures presence, presence or absence of highly stained 
structures, immersion oil, coverslip thickness etc.), controllable and 
uncontrollable experimental variables, or configuration problems with the 
microscope (e.g. optical component alignment, objective magnification, 
bleaching artifacts, aberrations, quantum efficiency, and the specimen 
embedding medium). 
In our experimental conditions, the immunofluorescence experiments were 
assessed by confocal microscopy TSC SP2 Leica. 
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3.6.1 Cell culture immunofluorescence  
Cell staining for confocal microscopy analysis was performed according to 
following procedures:  
Preparation of cover glasses:.  
o Wash cover glasses for 30 min in running tap water.  
o Rinse with dH20.  
o Incubate cover glasses in 40 µg/ml poly-L-lysine (MW ~70-90kDa) 
overnight at 37°.  
o Wash cover glasses for 1 hour in running tap water.  
o Rinse cover glasses 3 times for 5 min each in dH2O.  
o Dry cover glasses on filter paper in a dust-free area.  
o Sterilize cover glasses inside the laminar flow chamber under UV 
light for at least 4 hours.  
Cell culture  
o Detach cell from the plastic surface by incubating them in trypsin 
solution.  
o Resuspend detached cells in culture medium and transfer them to 
culture dishes with the cover glasses.  
o Culture cells up to semi-confluency.  
Paraphormaldeid fixation 
The paraformaldeid fixation is an easy and rapid fixation method. It works by 
precipitating cellular proteins onto the coverlslip.There is no need to 
permeablise the cells and there is no quenching of the fixative required. 
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However, this method has provided low structural cell preservation since lipids 
and soluble proteins are extracted from the cell.  
After cell fixation, the protocol used is the following: 
o Wash cells with PBS. Drain off culture medium and rinse cover slips with 
PBS. Drain off PBS with any of the above mentioned fixation methods.  
o Wash in PBS 3-times 5 min.  
o Permeabilize with 0.01% Triton X-100 in PBS for 30 sec (if needed).  
o Wash in PBS 3-times 5 min  
o Incubate in 1% BSA, PBS pH 7.5 for 30 min to block unspecific binding 
of the antibodies. (alternative blocking solutions are: 1 % gelatine, 1 % 
bovine or horse serum).  
o Incubate with primary antibody in 1% BSA, PBS pH 7.5 for 60 min (or 
over night at room temperature, depending on antibody concentration 
and the accessibility of the antigen).  
o Wash with PBS pH 7.5, 3-times 10 min.  
o Incubate 2nd antibody in 1% BSA, PBS pH 7.5, 60 min at room 
temperature.  
o Wash with PBS pH 7.5, 3-times 10 min.  
o Incubate in 0.1-1 mg/ml Hoechst or DAPI (DNA stain) for 10 min.  
o Rinse with PBS.  
o Mount in PPD-mounting medium.  
o Seal with nail polish.  
Primary antibodies used: 
o Phalloidin, (diluition 1:100 in PBS) (Molecular Probes). 
o Keratin 8-18, (diluition 1:100 in PBS) (Lab Vision). 
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o Caspase-3, (diluition 1:100 in PBS) (Santa Cruz Biotechnology). 
o EDA receptor, (diluition 1:100 in PBS) (R&D). 
o EDA1 (diluition 1:100 in PBS) (R&D). 
Secondary antibodies: 
o anti rabbit IgG (diluition 1:1000 in PBS) (Invitrogen). 
o anti goat IgG (diluition 1:1000 in PBS) (Invitrogen). 
o Anti mouse IgG (diluition 1:1000 in PBS) (Invitrogen). 
 
 
3.7 TUNEL assay 
 
The DeadEnd™ Fluorometric TUNEL System(a) is designed for the specific 
detection and quantitation of apoptotic cells within a cell population. The 
system is non-radioactive and provides for simple, accurate and rapid detection 
of apoptotic cells in situ at the single-cell level or in cell suspensions. The 
system can be used to assay apoptotic cell death in many systems, including 
cultured cells and formalin-fixed, paraffin-embedded tissue sections. The 
DeadEnd™ Fluorometric TUNEL System measures nuclear DNA 
fragmentation, an 
important biochemical hallmark of apoptosis in many cell types. 
 
3.7.1 Apoptosis Detection 
o Fix: Immerse slides in 4% formaldehyde in PBS for 25 minutes at 4°C. 
o Wash: Immerse slides twice in PBS, 5 minutes each time. 
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o Permeabilize: Immerse slides in 0.2% Triton® X-100 in PBS for 5 
minutes. 
o Wash: Immerse slides twice in PBS, 5 minutes each time. 
o Equilibrate: Add 100µl Equilibration Buffer. Equilibrate at room 
temperature for 5–10 minutes. 
o Label: Add 50µl of TdT reaction mix to the cells on an area no larger 
than 5 square centimeters. Do not allow cells to dry completely. Cover 
slides with Plastic Coverslips to ensure even distribution of the mix. 
Incubate slides for 60 minutes at 37°C in a humidif ied chamber; avoid 
exposure to light from this step forward. 
o Stop Reaction: Remove Plastic Coverslips. Immerse slides in 2X SSC 
for 15 minutes. 
o Wash: Immerse slides three times in PBS, 5 minutes each time. 
o Mount: Add mounting medium to slides. 
o Counterstain: To visualize all nuclei, use Vectashield® with DAPI. 
o Analyze: Detect localized green fluorescence of apoptotic cells by 
fluorescence microscopy. DAPI-stained nuclei will be blue. 
 
 
3.8 Prevention of protein degradation in ex-vivo hair bulbs   
 
Since drug treatment had a very favourable effects against apoptotic 
phenomena, it was relevant to test whether such treatment was also be 
affective in preventing the hair bulb decay following its extraction and in vitro 
incubation for 24 hours. In the first assay, 50 human hair bulbs were extracted 
by means of a fine forceps from a healthy donor. After the isolation the same 
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number of follicules were batched in PBS with proteases inhibitors (PMSF 
1mM; NaVO4 10mM and NaF 1 mM) in presence of absence of compound 
mixture A (SP 0.5 mg/cps; RU 2.5 mg/cps; ZEA 2 mg/cps) incubated for 
different times (0 min; 30 min and 24 hours) at 37°C in presence of 5% CO2.  
At the end of the incubation period, bulbs were centrifuged at 10.000xg for 1 
minute at room temperature. Supernatant was removed and the bulbs were re-
suspended  in 1 ml of trizolTM and processed for protein extraction (see 
materials and methods). Proteins were loaded on SDS gel electrophoresis 
under reducing and denaturing conditions. The activity of AKT and Erk was 
investigated by means of specific antibodies against phosphorylated forms of 
the protein 
A second ex-vivo assay was performed on hair bulbs from 3 healthy female 
subjects. 152 bulbs, after removal of the hair, were mixed and separated in 8 
vials for 8 different treatment conditions (19 bulbs for each treatment) following 
scheme outlined below.  
• Time of incubation =0’      
 Sample 1     - F   - Igf-1  
 “           2     - F   +Igf-1 
“            3     +F   - Igf-1 
“            4     +F   +Igf-1 
          
• Time of incubation =24h     
Sample 5     - F   - Igf-1 
“           6     - F   +Igf-1 
“           7     +F   - Igf-1 
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“           8     +F   +Igf-1 
• Mixture of compounds used: A (SP 0.5 mg/cps; RU 2.5 mg/cps; ZEA 2 
mg/cps)   
• Insulin growth factor-1 (IGF-1): 50ng/ml 
 
Insulin-like growth factor-I (IGF-1) and high-affinity IGF-binding proteins 
(IGFBPs)  are expressed in the hair follicle, suggesting a role of the IGF 
signalling pathway in follicle biology. In the skin, IGF-I has been reported to be 
exclusively expressed by mesenchymal cells of the dermis and the dermal 
papilla. Its receptor, IGF-1R, is synthesized in mesenchymal as well as in 
epithelial cells. Gene expression has been demonstrated for the dermal papilla 
and cells of the hair matrix. IGF-1, its receptor and several IGFBPs are 
expressed in various compartments of the human and murine hair follicle. In 
humans, IGF-binding protein 3 is mainly expressed in the dermal papilla of hair 
producing follicles. Further reports reveal the capability of keratinocytes to 
produce insulin-like growth factor binding protein 3 (Igfbp3). Furthermore, IGF-I 
appeared to be essential to maintain in vitro cultured human hair follicles in the 
active, hair producing state. IGF-I-mediated effects on differentiation processes 
in the hair follicle have not yet been reported. For this reason we investigated 
the effect of IGF-I (50 ng/ml) in our experimental conditions. 
Samples from 1 to  4 were immediately precipitated by centrifugation (see 
above), dissolved in 1 ml of trizolTM and processed for protein extraction. 
Samples from 5 to 8 were incubated at  37°C in pres ence of 5% CO2 for 24 
hours and at the end of incubation period they were processed as reported 
previously. Proteins concentration was determined by using the Bredford’s 
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method with BSA as a standard. The same amount of protein (50 g) was 
loaded on SDS acrylamide GEL and electroblotted on nitrocellulose membrane.  
 
We investigated the expression of following proteins: 
o AKT 
o PHOSPHO AKT 
o ERK 
o PHOSPHO ERK 
o PARP 
o EDAR 
 
 
3.9 Statistical Analysis 
 
Western blotting results were statistically evaluated using Fisher’s exact test 
and the t test; the immunohistochemical data were analysed using the χ2 test. 
All of the analyses were performed using Ministat 2000 (2.1 version, 
Pubblicazioni Medico Scientifiche, Udine, Italy) and GraphPad Prism 4.0 
software; p values of <0.05 were considered statistically significant. 
 
 
3.10 Materials 
Running buffer 1X 
192 mM Glycin (BDH; Manchester- UK) 
0.1% SDS (Sigma) 
25 mM Tris (Biorad) 
Sample buffer 2X 
0.5 M Tris-HCl (BDH) pH 6.8 
20% Glycerol (Sigma) 
10% SDS (Sigma) 
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0.1% Bromophenol blue (Biorad) 
0.5% ß-mercaptoetanol (Sigma). 
Transfer buffer 1X 
19 mM Glycin (BDH) 
2.5 mM Tris Base (Biorad) 
2% Methanol (BDH) 
Ponceaus red 
0.2% (w/v) Ponceau’s (Sigma) 
3% (w/v) TCA (Sigma) 
3% sulfosalicylic acid (Sigma) 
TBS 
20 mM Tris (Biorad) 
500 mM NaCl (BDH) 
T-TBS 0.05% or 0.1% 
20 mM Tris (Biorad) 
500 mM NaCl (BDH) 
0.05% or 0.1%Tween20 (BDH) 
Blocking buffer 
5% not fat milk powder (Merck; Francoforte - DH) in T-TBS 0.05%. 
Stripping solution 
2% SDS (Sigma) 
62.5 mM Tris-HCl pH 6.7 (BDH)  
100 mM β-mercaptoetanol (Sigma) 
Homogenization buffer 
25mM Tris-Hcl pH 7.4 (Biorad) 
1mM EGTA (BDH) 
250 mM Saccarose (BDH) 
1% NP40 (Sigma) 
1% Triton X-100 (BDH) 
0.4 mM EDTA (BDH) 
plus protease inhibitors: 
50 mM NaF (Sigma) 
1 mM NaVO3 (Sigma) 
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4 mM PMSF (Sigma) 
1 M Benzamidine (Sigma) 
1 M NaN3 (Sigma) 
10 µg/ml Aprotinin (Sigma) 
10 µg/ml Leupeptin (Sigma) 
Lowry-Ciocalteau’s protein assay  
BSA (Sigma) 
Na2CO3 al 2% (Merk) 
CuSO4 0.5% (BDH) 
NaK tartrato 1% (BDH) 
Folin Ciocalteau’s (Fluka; Buchs - SW) 
PBS 0.01 M 
137 mM NaCl (BDH) 
2.7 mM KCl (BDH) 
1.47 mM KH2PO4 (BDH) 
8.1 mM Na2HPO4 (BDH) 
in dH2O. 
 
Immunocytochemistry reagents 
Xilene (BDH) 
Ethanol 100% (BDH) 
sodium citrate 0.01M (pH=6) (Sigma) 
NH4Cl 0.05 M (BDH) 
H2O2 1% (Merck) 
BSA 1.5% (Sigma)  
Triton 0.2% (BDH) 
DAB 3% (Sigma) 
A549 complete medium  
87% RPMI1640 (Euro Clone; St. Louis - MO) 
10% FBS(Euro Clone) 
1% Penicillin G potassic salt (100 U/ml) (Euro Clone) 
1% Streptomicin Sul fate (100 µg/ml) (Euro Clone) 
1% Glutamine (Euro Clone).  
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Lysis buffer 
2% SDS (Sigma) 
0.1 M CH3COONa (Sigma) 
5 mM EDTA (BDH) 
in dH2O. 
TBE 1X  
0.009 M Tris Borate (Sigma)  
0.002 M EDTA (BDH) 
in H2OmQ. 
Loading dye 
0.025% bromophenol blue (Sigma) 
0.25% xilene cyanol (Sigma) 
30% Glycerol (BDH) 
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4. Results 
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4.1 Anti-apototic effect of compounds under investigation 
 
Apoptosis in HFDP cells  was induced by exposure to staurosporin added to 
the normal growth medium at the final concentration of 1µM. In figure 14 it is 
shown that staurosporin enhanced by about four fold the activity of caspase-3 
within 24 hours. A shorter incubation (6 hours) was ineffective and caspase-3 
activity did not increase. The experiment was run in duplicate.  
Figure 15. Induction of caspase-3 activity in presence of 1µM Staurosporin at 24  (    ) and 6       
(     ) hours.  
 
 
Thus the 24 hour incubation period was chosen as the experimental time 
frame. The action of investigated compounds was evaluated by adding them at 
the proper concentration to the growth medium immediately after 1µM 
staurosporin. Following the standard incubation period of 24 hours, cells were 
washed once with cold PBS (4°C), then proteins were  extracted  in lysis buffer 
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(provided by the supplier of caspase-3 assay kit).  Proteins concentration was 
determined by Quick Start™ Bradford method with BSA as a standard. The 
activity of caspase-3 was determined using 200 µg of total proteins. 
 
 
 
 Table 2. Concentrations of active principles applied used in the test of caspase-3 
activity 
 
 
 
[µM] 
 
[µg/ml] 
 
SPERMIDINE (SP) 
 
0.1 
 
0.026 
 
SPERMIDINE (SP) 
 
1 
 
0.264 
 
RUTIN (RU) 
 
2.2 
 
1.34 
 
RUTIN (RU) 
 
22 
 
13.42 
 
ZEAXANTHINE (ZEA) 
 
8 
 
4.54 
 
ZEAXANTHINE (ZEA) 
 
80 
 
45.44 
 
EPIGALLOCATHECHIN 
GALLATE (ECG) 
 
1.8 
 
0.824 
 
EPIGALLOCATECHIN 
GALLATE (ECG) 
 
18 
 
8,24 
 
 
The  active principles were added to the culture medium alone (figure 15) or in 
different combinations (figure 17).   
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Figure 16. Caspase-3 activity reduction by active principles ST staurosporine; SP 
spermidine; Ru rutin; ZEA zeaxanthin; ECG epigallocatechin gallate 
 
 
In figure 16 it is shown that Rutin alone at 22 µM concentration reduced by 50% 
the Staurosporin-induced caspase-3 activity, at the lower concentration the 
reduction was 35%. At best, Sperimidin (1µM) alone decreased the enzyme 
activity by 40% and Zeaxanthin (8 µM) above 30%. The higher zeaxanthin 
concentration resulted less effective. It was also observed that the addition of  
epigallocatechin gallate at the final concentration of 18µM (EGCG 18) to 
staurosporin had a negative impact on cellular morphology and preservation. 
After 24 hours cells were broken into pieces. This may explain the lack of 
Absorbance shown  in figure 16.  
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 Figure 17. Caspase-3 activity reduction by different combinations of two anti-apoptotic 
   principles. ST staurosporine; SP spermidine; Ru rutin; ZEA zeaxanthin. 
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Figure 18.  Caspase-3 activity reduction by different combinations of three active 
principles. ST staurosporine; SP spermidine; Ru rutin; ZEA zeaxanthin. 
 
 
 
 
The association of Rutin with Sperimidin (1µM) or Zeaxanthin ( 80 µM) 
enhanced its inhibition on the apoptotic process. In particular the addition of 
spermidin allowed the best inhibition of caspase- 3 activity with Rutin at 2.2 µM, 
while the higher concentration of Rutin (22µM) was less effective when 
associated to sperimidin (1µM). Also of interest the boosting effect obtained 
with the addition of 22µM Rutin to 80 µM Zeaxanthin that alone reduced 
caspase activity by 25% and with Rutin addition its effect increased to 60% 
reduction.
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Table 3. The anti-apoptotic actions of investigated compounds as a single molecule o in 
different combinations was reported as percent of caspase-3 activity inhibition. 
 
 ACTIVE 
 PRINCIPLES  
[µM] 
 
CASPASE-3 
ACTIVITY 
(%) 
ST 1 µM // 100 
“ SP 0.1 78,36 
“ SP 1 63,1 
“ RU 2.2 67,9 
“ RU 22 53,73 
“ ZEA 8 71 
“ ZEA 80 86,8 
“ EGCG 1.8 101 
“ EGCG 18 0 
   
“ RU 2.2 +ZEA 8 71,67 
“ RU 2.2 +SP 0.1 57,68++ 
“ RU 2.2 +SP1 43,68+++ 
“ RU 2.2 +ECG 1.8 85,32- 
“ RU 22+ZEA 8 65,87 
“ RU 22+ZEA 80 40,95+++ 
“ SP 0.1+ ZEA 8 64,84+ 
“ SP 0.1+ ZEA 80 54,61++ 
“ SP1+RU22 75,085? 
“ SP1+ZEA8 71,67 
“ SP1+ZEA80 62,11 
“ ECG 1.8+SP 0.1 89,07* 
“ ECG 1.8+SP 1 78,5* 
“ ECG 1.8+RU 22 85,32* 
“ ECG 1.8+ZEA 8 89,078* 
“ ECG 1.8+ZEA 80 84,3* 
“ RU 2.2+ ZEA 80 54,89+ 
“ RU 22+SP 0.1 60,14+ 
   
“ RU 2.2 +SP 0.1+ZEA 8 48,25 
“ RU 2.2 +SP 0.1+ ZEA 80 51,7 
“ RU 22+ SP0.1+ ZEA 8 49,6++ 
“ RU 22+ SP0.1 + ZEA 80 40,21 ++ 
“ RU 2.2 +SP1+ZEA 8 44,7 
“ RU 2.2 +SP1+ZEA 80 46,8 
“ RU 22 +SP1+ZEA 8 68,53 
“ RU 22 +SP1+ZEA 80 61,53 
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4.2 Morphological and biochemical evaluation of the anti-
apoptotic action of the three active principles 
 
The actions of spermidine, rutin and zeaxanthin in counteracting apoptosis 
induced by staurosporin was also investigated by means of 
immunocytochemistry and western blot analyses. 
HFDP cells are flat and with different morphologies. The actin cytoskeleton 
(phalloidin) is distributed through the cell, while ketain-18 is more concentrated 
around cell nucleus (figure 19). 
The staurosporin exposure resulted in a marked activation of Caspase-3 
accompanied by cytoskeletal degradation, nuclear blebbing, and cellular 
fragmentation (Fig. 19 panel A and B).  Such a cellular destruction is totally 
prevented by the combined treatment (SP 0.5 mg/cps; RU 2.5 mg/cps; ZEA 2 
mg/cps). The extent  of cell loss was greatly reduced, and, differently from 
untreated cells, there was a total preservation and normal distribution of actin-
tubulin cytoskeleton with normal cellular shape, as evidenced by the labelling 
with phalloindin . Caspase-3 is normally present around the nucleus, and is 
increased throughout the cell after staurosporin exposure (figure 19B). 
Following co-administration of Staurosporin and combined treatment, the cell 
loss is reduced and cellular morphology is preserved (figure 19B). It must be 
noted however that, differently from control, caspase-3 is distributed throughout 
the cell (figure 19B, ST+ drug treatment). 
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Figure 19. HPDF cellular morphology and apoptosis. A) Red= keratine 8-18; Green= 
phalloidin; Blue= DAPI; B) Red= caspase-3 (total); Green=phalloidin; Blue=DAPI; C) Shape of 
cells; D) caspase-3 activity measured with the amount of compounds used in the assay. 
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B: Red= caspse-3; Green=phalloidin; Blue=DAPI 
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The interference microscopy (figure 19C) shows that the few viable cells 
treated with staurosporin are atrophic, with poor cytoplasm around the nucleus 
and large vacuolarization. Treatment with the active principles counteracts  
staurosporin action and maintains the cellular shape and reduces markedly the 
vacuolarization. In figure 17 D it is shown how staurosporin increased caspase-
3 activity by 5 fold and that the chosen treatment is able to reduce it by 75%. 
The inhibition of apoptosis was also investigated by western blotting (figure 19A 
and 19 B) throughout the evaluation of the effect of drug treatment on caspase-
3  and Poly (ADP-ribose) polymerase (PARP), a protein involved in a number 
of cellular processes of  DNA repair and programmed cell death. Upon DNA 
cleavage by enzymes involved in cell death (such as caspases), PARP can 
deplete cellular ATP in an attempt to repair the damaged DNA. ATP depletion 
in a cell leads to lysis and cell death.  
HFDP cells exposure to staurosporin for 24 hours induced the expression of 
caspase-3. The increase was about three fold above the control, also PARP 
expression resulted largely induced (figure 19 A and 19 B). The treatment with 
two different combinations of SP, RU and ZEA significantly counteracted the 
effect of staurosporin inhibiting the expression of both capsase-3 and PARP 
(figure 19 A and 19 B).  
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A) 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Expression of caspase-3 and PARP. A) The expression of the proteins was 
evaluated by western blotting using specific polyclonal antibodies; B) quantification of bands 
reporting the optical density (O.D.) expressed as percent of staurosporin treatment.  A = SP 0.5 
mg/cps; RU 2.5 mg/cps; ZEA 2 mg/cps B = SP 0.5 mg/cps; RU 2.5 mg/cps; ZEA 4 mg/cps 
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The efficacy of the drug treatment on apoptosis is further supported by the 
evaluation of the activity of Akt and MAP kinases ERK1/2 (figure 21 panel A 
and B), that resulted significantly impaired after cell incubation for 24 hours with 
staurosporin. The phosphorylated form of both Akt and ERK1/2 is greatly 
readuced by staurosporin, while  the enzyme expression is unaffected. The two 
drug-combinations resulted in the full preservation of the phosphorylated forms, 
with no changes in enzyme expression.  
A) 
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β actin 
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                                            Akt quantification of bands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Maintenance of Akt and ERK phosphorylation. A) The expression of the proteins 
was evaluated by western blotting using specific polyclonal antibodies; B) quantification of 
bands reporting the optical density (O.D.) expressed as percent of  control (CTRL).  A = SP 0.5 
mg/cps; RU 2.5 mg/cps; ZEA 2 mg/cps B = SP 0.5 mg/cps; RU 2.5 mg/cps; ZEA 4 mg/cps. 
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4.3 Investigation of EDA-A1/EDAR  expression 
 
Two receptors for EDA, EDAR and EDA2R, are specific for the two isoforms 
EDA-A1 and EDA-A2, respectively. EDA-A1 and its receptor EDAR are capable 
of activating the NF-kB pathway and are implicated in hair growth. EDA2R is 
capable of activating the NF-kB pathway and also through TRAF3,6, JNK (c-
Jun N-terminal kinase), which activates c-Jun. Mutations in EDA and EDAR 
give rise to ectodermal dysplasia, a clinical syndrome characterized by loss of 
hair, sweat glands, and teeth, whereas mutations in EDA2R do not. EDA2R 
could influence the onset of AGA through the activation of the NF-kB pathway 
or by c-Jun, which has been shown to be critical for Androgenetic Receptor  
transactivation. The expression of EDAR was investigated by means of both 
immunocytochemistry and western blotting analyses. While the expression of 
EDA was studied only by immunocytochemistry. Both methods show that 
EDAR expression in HFDP cells is reduced by apoptosis and much more by 
drug treatment. Differently, EDA expression is increased by staurosporin 
exposure and is abolished by drug treatment. 
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Figure 22. EDAR expression. 
 
A) 
 
Red= caspase-3;  Green= EDA receptor;  Blu=DAPI. 
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C) 
 
 
 
 
 
Red= caspase-3; Green= EDA1; Blu=DAPI 
 
Figure22. EDAR/EDA1 expression. A) The expression of the proteins was evaluated by 
western blotting using specific polyclonal antibodies. The treatment used in the 
immunoflurescence is referred to the incubation of mixture A. We obtained the same results 
with the mixture B. A = SP 0.5 mg/cps; RU 2.5 mg/cps; ZEA 2 mg/cps B = SP 0.5 mg/cps; RU 
2.5 mg/cps; ZEA 4 mg/cps 
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4.4 TUNEL assay 
 
 
 
Fig. 23 Quantification of apoptotic cells  with The DeadEnd™ Fluorometric TUNEL System   
A= Rutin 2,5mg/cps, Spermidine 0,5 mg/cps, Zeaxanthin 2 mg/cps;  
  
 
The DeadEnd™ Fluorometric TUNEL System was elaborated for the specific 
detection and quantification of apoptotic cells in a defined cell culture. After 
fixing cells with paraphormaldeid  we performed Fluorimetric assay, counted 
apoptotic cells (green) and total cells in each box, and we made the statistical 
analysis. The higher percentage of apoptotic cells is present in staurosporin-
treated group. As it is shown in figure 23, the number of staurosporin-induced 
Tunel positive cells is significantly decrease by the treatment. 
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4.5 HFDP cells proliferation 
HFDPC proliferation 4 05 2010
0
30
60
90
120
150
180
210
240
270
300
330
at plating 3 5 8
Days in culture
N°
 
o
f c
el
ls
 
(x1
00
0)
CTR
RU
Amix
N°
 
o
f c
el
ls
 
(x1
00
0)
 
Fig. 24  Proliferation curve of HFDP cells after 3,5 and 8 days. A= Rutin 2,5mg/cps, Spermidine 
0,5 mg/cps, Zeaxanthin 2 mg/cps. 
 
We also tested this three active principles on cells proliferation. Results are 
shown in figure 24, cells are treated with the mixture of rutin, spermidine and 
zeaxanthin, and also by rutin alone. At three days the number of treated cells is 
comparable among treated and no-treated ones. At 5 days a clear difference 
among the three groups can be noticed. Treated cells are an higher number 
suggesting an effect of these agents on proliferation. After  8 days the number 
of non treated cells is definetly lower than the others. Rutin appears as effective 
as the mixture in enhancing HFDP cells proliferation. 
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4.6 Prevention of protein degradation in ex-vivo hair bulbs   
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Figure 25. Prevention of protein degradation in ex-vivo bulbs. A) The expression of the 
proteins was evaluated by western blotting using specific polyclonal antibodies.  
B) quantification of bands reporting the optical density (O.D.) expressed as percent of  control 
(0’).   
 
Ex-vivo human hair bulbs were incubated for 24 hoursin cells culture medium at 
37°C. After 24 hours hair were homogenised and proc essed for western 
blotting evaluation of the expression and function ofkey cellular proteins such 
as AKT and ERK. The incubative period caused the degradation of both 
phosphorylated and basal forms of AKT and ERK (Fig. 25). The addition to the 
incubation medium of the mixture led to the complete preservation of both 
proteins in basal and phosphorylated forms. The degradation was 
observedalso for actin, that was fully maintained by the treatment. 
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- = Control    
IGF-1= 50 ng/ml     
T= Rutin 2,5mg/cps, Spermidine 0,5 mg/cps, Zeaxanthin 2 mg/cps;  
C+= protein extract from A549 cells, used as a positive control 
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ERK quantification of bands 
 
PARP quantification of bands 
 
 
Figure 26. Prevention of protein degradation in ex-vivo bulbs (2° experiment).  A) The 
expression of the proteins was evaluated by western blotting using specific polyclonal 
antibodies. B) quantification of bands reporting the optical density (O.D.) expressed as percent 
of  control (0’).   
  
 
Exposure of hair bulbs to IGF-1 enhances phosphorilation of AKT and slightly 
also ERK. Following 24 hours incubation, bulbs do not show any more 
detectable amounts of AKT, ERK, and PARP. However the presence of the 
mixture prevents such a drop in protein content and re-establish the IGF-1 
dependent phosphorylation of AKT. 
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5. Discussion 
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Androgenetic alopecia is a genetically determined disorder and is progressive 
through the gradual conversion of terminal hairs into indeterminate hairs and 
finally to vellus hairs. [Osborn].  Patients with androgenetic alopecia have a 
reduction in the terminal-to-vellus hair ratio, normally about 4:1. Following 
miniaturization of the follicles, fibrous tracts remain. Patients with this disorder 
usually have a typical patterned distribution of hair loss. [Otberg et al.]. The 
onset of androgenetic alopecia is gradual. Men present with gradual thinning in 
the temporal areas, producing a reshaping of the anterior part of the hairline. 
For the most part, the evolution of baldness progresses according to the 
Norwood/Hamilton [Norwood et al.] classification of frontal and vertex thinning. 
Women with androgenetic alopecia usually present with diffuse thinning on the 
crown. Bitemporal recession does occur in women but usually to a lesser 
degree than in men. In general, women maintain a frontal hairline. 
Androgenetic alopecia is essentially a cosmetic disorder, other than affecting 
the patient psychologically [Cash; Stough et al.]. 
Cycling of hair follicles in the mouse has been intensively investigated from the 
histological and molecular viewpoints. It is clear that the mammalian hair follicle 
is an extremely complex organ that undergoes periods of growth (anagen), 
involution (catagen), and quiescence (telogen) [Courtois et al.]. Mediators 
suspected of dictating the cyclic action of the follicles in the murine model 
include dozens of biochemicals that have been studied in other cell signaling 
pathways, including those involved with the initiation of apoptosis or 
programmed cell death [Weinberg et al.]. In 1997, Lindner et al mapped the 
expression of biochemical mediators throughout the follicular cycle of mice, 
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demonstrating the complex association of biochemical signaling with follicular 
phase changes [Lindner et al.]. 
The mesenchyme-derived dermal papilla plays a major regulatory role in the 
complex cell biology of the hair follicle. The ability to culture dermal papilla cells 
from a range of species and particularly a range of normal and disordered 
human hair follicles has enabled the development of a powerful new model 
system for investigating hair follicle biology. Already these studies have 
reinforced the importance of dermal papilla cells in initiating new follicle growth 
and in androgen action in human hair follicles [Oliver et al.]. The retention of 
hair growth inducing capabilities and characteristics that reflect their in vivo 
responsiveness to androgens in culture means that they offer a potentially 
useful approach despite significant drawbacks in working with the cells 
themselves [Ohtsuki et al.]. Further studies using dermal papilla cells may well 
elucidate key molecules involved in hair biology in health and disease and, 
thereby, lead to better therapeutic regimens [Randall]. 
Research in and around apoptosis has increased substantially since the early 
1990s. In addition to its importance as a biological phenomenon, defective 
apoptotic processes have been implicated in an extensive variety of diseases.  
Sequential activation of caspases plays a central role in the execution-phase of 
cell apoptosis. Caspases exist as inactive proenzymes that undergo proteolytic 
processing at conserved aspartic residues to produce two subunits, large and 
small, that dimerize to form the active enzyme. A member of this family, 
caspase-3 (CPP32, apopain, YAMA) has been identified as being a key 
mediator of apoptosis of mammalian cells [Kothakota et al.]. Our study was 
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mostly focused on the activity of this enzyme. Its activity was measured by a 
specific assay. 
The experiment was firstly run testing 4 different non synthetic molecules and 
measuring the activity of the enzyme when Staurisporin 1 microM was added to 
the cells. The strongest effect was after 24 hours and it could produce an effect 
very close to catagen. By reproducing a natural effect in our  cells we tested the 
principles. 
Epigallocatechin gallate was excluded at the beginning of the job. Its action did 
not inhibit the activity caspase-3. 
Spermidine and rutin, utilized as single active principle are the most affective 
compounds capable of inhibiting the increase of caspase-3 activity induced by 
staurosporin. Rutin at the concentration of 22 µM (RU 22) reduced caspase-3 
activation by about 50%.  Many combinations of two compounds resulted to be 
much more effective, than the compounds alone, in the inhibition of caspase-3 
activity (underlined in yellow in the summary table). In particular the 
combinations  RU2.2 + SP1, RU22 + ZEA80 e SP 0.1 + ZEA 80 reduced the 
activity of caspase-3 by 60%. 
 When the combination contained the three active principles, we observed an 
action by promoting zeaxanthin (in green in summary table), that as single 
agent was not particularly effective. Zeaxanthin, when added to the 
combination of RU+SP, ameliorated the action of the two drugs co-
administrated.  
The inhibition of caspase-3 activity is associated to a reduced enhancement of 
caspase-3 expression by staurosporin treatment. Apoptosis as a different 
course. Morphologically the protective effects of drugs was even more 
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remarkable, as staurosporin caused cellular blebbing and destruction. Drug 
exposure protected HFDP cells allowing the maintainance of normal 
cytoskeletal cellular structure.  
In treated cells phalloidin one of cytoskeleton markers is still visible, where in 
apoptotic cells is mostly disappeared; it means that the regular shape is kept, 
compared to the control one. Also the structure of the cytokeratin Keratin 8-18 
is still visible where in apoptotic cells is less. As we can see in images the 
treated cells shape is very close to the control ones.  
Tunnel assay, a specific assay to remark apoptosis, shows that apoptosis is 
strongly reduced in treated cells. 
The result we obtained, using the three principles without staurosporin, is that 
its action is not only apoptosis dependent but it can also play a key role in 
cellular growing and differentiation. 
 We may conclude that array of in-vitro and ex-vivo evidences show the 
effectiveness of these active principles in preventing hair bulb cellular apoptosis 
and in maintaining expression and function of key enzymes such as Akt and 
MAP kinases. 
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